News Flash: Analysts Just Made A Substantial Upgrade To Their MedinCell S.A. (EPA:MEDCL) Forecasts

MedinCell S.A. (EPA:MEDCL) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The analysts have sharply increased their revenue numbers, with a view that MedinCell will make substantially more sales than they'd previously expected. The stock price has risen 4.2% to €16.46 over the past week, suggesting investors are becoming more optimistic. Could this big upgrade push the stock even higher?

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Following the upgrade, the current consensus from MedinCell's four analysts is for revenues of €40m in 2026 which - if met - would reflect a substantial 44% increase on its sales over the past 12 months. Losses are expected to turn into profits real soon, with the analysts forecasting €0.36 in per-share earnings. Previously, the analysts had been modelling revenues of €36m and earnings per share (EPS) of €0.14 in 2026. So we can see there's been a pretty clear increase in analyst sentiment in recent times, with both revenues and earnings per share receiving a decent lift in the latest estimates.

View our latest analysis for MedinCell

Although the analysts have upgraded their earnings estimates, there was no change to the consensus price target of €22.77, suggesting that the forecast performance does not have a long term impact on the company's valuation.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the MedinCell's past performance and to peers in the same industry. The analysts are definitely expecting MedinCell's growth to accelerate, with the forecast 44% annualised growth to the end of 2026 ranking favourably alongside historical growth of 25% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 4.9% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect MedinCell to grow faster than the wider industry.

The Bottom Line

The most important thing to take away from this upgrade is that analysts upgraded their earnings per share estimates for this year, expecting improving business conditions. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at MedinCell.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At Simply Wall St, we have a full range of analyst estimates for MedinCell going out to 2028, and you can see them free on our platform here..

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.